HuGE Literature Finder
Records 1-5
|
Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.
PloS one 2017 12 (6): e0178450. Stafford Jaime L, Dyson Gregory, Levin Nancy K, Chaudhry Sophia, Rosati Rita, Kalpage Hasini, Wernette Courtney, Petrucelli Nancie, Simon Michael S, Tainsky Michael |
|
Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.
Pharmacogenomics 2014 Feb 15 (3): 329-37. Khrunin Andrey V, Khokhrin Denis V, Moisseev Alexey A, Gorbunova Vera A, Limborska Svetlana |
|
Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007 Dec 16 (12): 2557-65. Beesley Jonathan, Jordan Susan J, Spurdle Amanda B, Song Honglin, Ramus Susan J, Kjaer Suzanne Kruger, Hogdall Estrid, DiCioccio Richard A, McGuire Valerie, Whittemore Alice S, Gayther Simon A, Pharoah Paul D P, Webb Penelope M, Chenevix-Trench Georgia, , , |
|
RAD52 Y415X truncation polymorphism and epithelial ovarian cancer risk in Australian women.
Cancer letters 2005 Feb 218 (2): 191-7. Kelemen Livia, Spurdle Amanda B, Purdie David M, Gertig Dorota, Chenevix-Trench Georg |
|
Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients.
Oncology reports 0 10 (5): 1551-3. Tong Dan, Volm Tanja, Eberhardt Elke, Krainer Michael, Leodolter Sepp, Kreienberg Rolf, Zeillinger Robe |
- Page last reviewed:Oct 1, 2020
- Page last updated:Sep 16, 2021
- Content source: